MAXCYTE, INC. — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 64/100
What the filing says
MaxCyte raised full-year 2026 revenue guidance from $30–32M to $34M (consisting of ~$28M core business revenue vs. prior $25–27M guidance, plus ~$6M SPL Program revenue vs. prior ~$5M). Q3 2026 preliminary revenue: ~$8.1M core business (26% YoY growth) plus >$1.0M SPL Program revenue including $1.0M milestone. Growth driven by accelerated instrument purchases from a large customer moved forward from Q4; company achieved second SPL milestone in 2026 and now supports two pivotal trials with potential approval as early as 2027.
Why this rating
Guidance raise of ~$2–4M (6–13% vs. midpoint) is meaningful for $230.7M market-cap company. Double-digit growth recovery and milestone achievements signal business momentum and SPL partnership progress, materially supporting narrative change from decline to growth.
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.